Wendy started her career as an epidemiologist in cancer research with the design of early phase clinical trials. She has successfully achieved approval for a number of CTA/IND filings and NDS/NDA filings in Canada, the US and Europe. Previous positions include Director of Research at Knoll Canada where she was instrumental in the clinical development of several human monoclonal antibodies (Humira®), Senior Director, Clinical Research at GlycoDesign and R&D Director, Inflammation and Neurology at Amgen Canada. As a private consultant, she has assisted biotechnology companies in preparing and executing strategic clinical and regulatory development plans for products and devices and in performing due diligence on products for potential investors. In the past, Wendy has served as an advisor to start-up companies in the health sector through the MaRS network. She is currently the Director of Clinical Development for the International Consortium on Anti-Virals (ICAV), a not-for-profit drug development initiative focused on finding treatments for neglected and emerging viral diseases.